Bui Patricia T A, Stattin Martin, Ahmed-Balestra Daniel, Kickinger Stefan, Krepler Katharina, Ansari-Shahrezaei Siamak
Karl Landsteiner Institute for Retinal Research and Imaging, Vienna, Austria.
Vienna Health Care Group Clinic Landstraße, Department of Ophthalmology and Optometry, Vienna, Austria.
Eye (Lond). 2025 Apr;39(6):1183-1192. doi: 10.1038/s41433-024-03571-7. Epub 2025 Jan 6.
To investigate the long-term impact of half-fluence photodynamic therapy (PDT) on chorioretinal architecture in chronic central serous chorioretinopathy (cCSCR) through novel choroidal vascularity index (CVI) versus previously established subfoveal choroidal thickness (SFCT).
This post-hoc analysis included prospectively collected swept-source optical coherence tomography (SS-OCT) images of a total of 29 cCSCR and fellow eyes (FE), acquired before, one and 12 months after PDT. CVI, total choroidal area (TCA), luminal area (LA) and stromal area (SA) were calculated using validated binarization technique. Central macular thickness (CMT), SFCT and subretinal fluid (SRF) were assessed. Longitudinal changes following PDT and associations between all parameters were investigated.
CVI, TCA, LA, SFCT and CMT significantly decreased at month 1 (all p < 0.001). From month 1 to 12, CVI (p < 0.001) and LA (p = 0.01) increased but remained significantly lower than at baseline (p = 0.001 and p < 0.001). SFCT and CMT remained stable (all p = 1.0). SA and all FE parameters showed no significant changes at any time point. Comparing affected and FE, there were significant CVI differences at baseline (p < 0.001), month 1 (p = 0.01) and 12 (p < 0.001). SRF was significantly associated with higher CVI (p < 0.001), LA (p = 0.031), SFCT (p = 0.038).
Half-fluence PDT significantly affects choroidal architecture, with sustained CVI and SFCT reductions 12 months post-treatment. Use of CVI as both a treatment response and disease activity marker is merited. There is a large discrepancy between CVI and SFCT, suggesting they each represent different anatomic responses. CVI proves to be a more specific and reliable CSCR biomarker than previously established SFCT.
通过新型脉络膜血管指数(CVI)与先前确立的中心凹下脉络膜厚度(SFCT),研究半剂量光动力疗法(PDT)对慢性中心性浆液性脉络膜视网膜病变(cCSCR)脉络膜视网膜结构的长期影响。
这项事后分析纳入了前瞻性收集的共29例cCSCR患者及其对侧眼(FE)的扫频源光学相干断层扫描(SS-OCT)图像,这些图像在PDT治疗前、治疗后1个月和12个月获取。使用经过验证的二值化技术计算CVI、脉络膜总面积(TCA)、管腔面积(LA)和基质面积(SA)。评估中心黄斑厚度(CMT)、SFCT和视网膜下液(SRF)。研究PDT后的纵向变化以及所有参数之间的关联。
在第1个月时,CVI、TCA、LA、SFCT和CMT均显著降低(所有p<0.001)。从第1个月到第12个月,CVI(p<0.001)和LA(p=0.01)有所增加,但仍显著低于基线水平(p=0.001和p<0.001)。SFCT和CMT保持稳定(所有p=1.0)。SA和所有FE参数在任何时间点均无显著变化。比较患眼和FE,在基线(p<0.001)、第1个月(p=0.01)和第12个月(p<0.001)时CVI存在显著差异。SRF与较高的CVI(p<0.001)、LA(p=0.031)、SFCT(p=0.038)显著相关。
半剂量PDT显著影响脉络膜结构,治疗后12个月CVI和SFCT持续降低。将CVI用作治疗反应和疾病活动标志物是有价值的。CVI和SFCT之间存在较大差异,表明它们各自代表不同的解剖学反应。事实证明,CVI是一种比先前确立的SFCT更特异、更可靠的CSCR生物标志物。